Last reviewed · How we verify
NCT05760092
The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.
Phase 2 trial testing Institutional standard treatment for xerostomia and Long Covid in Xerostomia in 10 participants. Completed in 8 March 2024.
1 February 2024
Quick facts
| Lead sponsor | University of Nove de Julho |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 March 2023 |
| Primary completion | 1 February 2024 |
| Estimated completion | 8 March 2024 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Institutional standard treatment for xerostomia and Long Covid
- Photobiomodulation Therapy
- Placebo Photobiomodulation Therapy
Conditions studied
- Xerostomia — all drugs for Xerostomia →
- COVID-19 — all drugs for COVID-19 →
- Long COVID — all drugs for Long COVID →
- Persistent COVID-19 — all drugs for Persistent COVID-19 →
Sponsor
University of Nove de Julho
Who can join
Eligibility, any sex, with Xerostomia or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronavirus (COVID-19) is a newly emerging zoonotic agent that emerged in December 2019 in China (2019-nCoV) as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2). Long COVID-19, or Post-Covid Syndrome or Long-term COVID-19, is a post-viral syndrome that persists after the acute infection has resolved. The most frequent symptoms of Lonf-term COVID are fatigue and dyspnea. But two classes of symptoms have been received scientific attention: the musculoskeletal pain and oral complaints related to Long COVID, mainly xerostomia and burning mouth. Photobiomodulation (PBM) therapy is often used for oral diseases and presents itself as a non-invasive, low-cost, safe therapy that has benefits in relation to the quality of life of patients with xerostomia. This study aims to investigate the clinical effectiveness of the use of a Photobiomodulation protocol in the treatment xerostomia and oral complaints related to Long-Covid. This will be a single-center, randomized, controlled, blinded clinical trial that will involve patients with Long COVID in follow-up at the Medical and Multiprofessional outpatient clinic of University Nove de Julho (UNINOVE) which remained hospitalized with COVID-19 at Lydia Storópoli Universitarian Hospital during the year 2022 and who were discharged from the inpatient treatment from January to December 2022. All those patients presenting xerostomia, burning mouth or oral complaints related to Long Covid will be randomized into 2 groups: PBM Group (standard rehabilitation treatment for Long COVID and xerostomia + PBM therapy) or PBM placebo group (standard rehabilitation treatment for Long COVID and xerostomia + placebo PBM therapy). PBM consists of the application of Red LED on the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, 3 J/cm2, for 36 seconds, twice a week for 06 weeks. Functional and quality of life evaluations will be perform pre and post therapy period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05760092
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Xerostomia
Currently open trials in the same condition.
- NCT07394842 — Longitudinal Oral Health Changes After Head and Neck Radiotherapy · active not recruiting
- NCT06465628 — Acupressure on Xerostomia in Head and Neck Cancer Patients · NA · recruiting
- NCT06365047 — Dry Mouth Toothpaste Study - Comparing Two Toothpastes With Arginine · Phase 3 · active not recruiting
- NCT06194123 — Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis · NA · active not recruiting
- NCT06287294 — An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer · recruiting
Other University of Nove de Julho trials
Trials by the same sponsor.
- NCT07501143 — Effects of Physical Training in Patients With Advanced Heart Failure · NA · not yet recruiting
- NCT07525310 — Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients · NA · not yet recruiting
- NCT06984796 — Photobiomodulation on Pain Perception During the Insertion of the T 380 Copper Intrauterine Device (IUD) · NA · not yet recruiting
- NCT07302204 — Efficacy of Aerobic Exercise Versus Therapeutic Exercises on Exercise-induced Hypoalgesia in Knee Osteoarthritis · NA · recruiting
- NCT07033039 — Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05760092 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Nove de Julho
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05760092.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing